NCT00479401 Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients Status COMPLETED Phase PHASE3
NCT00472199 Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS) Status COMPLETED Phase PHASE4
NCT00467740 Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma Status COMPLETED Phase PHASE2
NCT00452400 Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD. Status COMPLETED Phase PHASE2
NCT00447902 Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation Status TERMINATED Phase PHASE3
NCT00440271 SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC Status TERMINATED Phase PHASE3
NCT00431067 Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy Status COMPLETED Phase PHASE2
NCT00425854 An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer Status COMPLETED Phase PHASE2
NCT00422162 A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression Status COMPLETED Phase PHASE4
NCT00412204 Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise Status COMPLETED Phase PHASE4
NCT00408993 Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China Status COMPLETED Phase PHASE3
NCT00406848 A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients Status COMPLETED Phase PHASE4
NCT00405236 Effect of Tiotropium on Inflammation and Exacerbations in COPD Status COMPLETED Phase PHASE4
NCT00405171 Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia Status COMPLETED Phase PHASE4
NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. Status RECRUITING Phase N/A
NCT00402233 A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients Status COMPLETED Phase PHASE4